Key result
Treatment with AT1-receptor antagonists losartan or irbesartan reduced glomerular macrophage/monocyte invagination in nephritic rats by approximately 30-50% and significantly reduced MCP-1 expression.
Why the study?
Do AT1-receptor antagonists reduce glomerular MCP-1 expression and macrophage/monocyte influx in a rat model of ATS-induced nephritis?
Do AT1-receptor antagonists reduce glomerular MCP-1 expression and macrophage/monocyte influx in a rat model of ATS-induced nephritis?
Short-term AT1-receptor antagonism reduces early glomerular MCP-1 expression and macrophage/monocyte influx in experimental nephritis, suggesting an immunomodulatory role for angiotensin II.
No takes yet. Share an insight, caveat, or question.
Does not alter human glomerulonephritis management; leaves open translation of AT1 blockade effects on MCP-1 and macrophage influx.
Wolf et al. (1998) studied Anti-thymocyte serum (ATS)-induced nephritis. AT1-receptor antagonists (losartan and irbesartan) vs. Control nephritic rats was evaluated on Glomerular macrophage/monocyte (M/M) invagination and MCP-1 expression. Treatment with AT1-receptor antagonists losartan or irbesartan reduced glomerular macrophage/monocyte invagination in nephritic rats by approximately 30-50% and significantly reduced MCP-1 expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: